Crystal Structures of Phosphodiesterases 4 and 5 in Complex with Inhibitor 3-Isobutyl-1-methylxanthine Suggest a Conformation Determinant of Inhibitor Selectivity*
暂无分享,去创建一个
H. Ke | Yudong Liu | J. Corbin | Q. Huai | S. Francis | Qing Huai | Yudong Liu | Hengming Ke | Sharron H. Francis | Jackie D. Corbin
[1] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[2] E. Degerman,et al. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). , 1995, Cellular signalling.
[3] J. Corbin,et al. 9 – Design and Synthesis of Xanthines and Cyclic GMP Analogues as Potent Inhibitors of PDE5 , 1996 .
[4] E. Degerman,et al. cGMP-inhibited phosphodiesterases (PDE3 gene family). , 1996, Biochemical Society transactions.
[5] Jorge Navaza,et al. [33] AMoRe: An automated molecular replacement program package. , 1997, Methods in enzymology.
[6] Weng-Lang Yang,et al. Reinventing the Wheel of Cyclic AMP , 2002 .
[7] J. Corbin,et al. Cyclic GMP Phosphodiesterase-5: Target of Sildenafil* , 1999, The Journal of Biological Chemistry.
[8] J. Corbin,et al. Histidine-607 and histidine-643 provide important interactions for metal support of catalysis in phosphodiesterase-5. , 2000, Biochemistry.
[9] J. Corbin,et al. Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. , 1994, The Journal of biological chemistry.
[10] S. Waldman,et al. Guanylyl cyclases and signaling by cyclic GMP. , 2000, Pharmacological reviews.
[11] Raymond Greene,et al. Trends in Endocrinology , 1969 .
[12] Jin Hwan Kim,et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules , 2003, Nature.
[13] Joseph Markowitz,et al. Crystal structure of phosphodiesterase 4D and inhibitor complex1 , 2002, FEBS letters.
[14] M. Giovannoni,et al. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. , 2000, European journal of medicinal chemistry.
[15] Hwa-Young Kim,et al. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. , 2003, Structure.
[16] M. Movsesian. Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure , 2000, Expert opinion on investigational drugs.
[17] J. Beavo,et al. Effects of xanthine derivatives on lipolysis and on adenosine 3',5'-monophosphate phosphodiesterase activity. , 1970, Molecular pharmacology.
[18] D. Underwood,et al. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. , 2000, Current opinion in pulmonary medicine.
[19] D. Pelligrino,et al. Cyclic nucleotide crosstalk and the regulation of cerebral vasodilation , 1998, Progress in Neurobiology.
[20] M. Fitzgerald,et al. Phosphodiesterase 4 inhibitors for the treatment of COPD. , 2002, Chest.
[21] G. Livera,et al. Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling* , 2003, The Journal of Biological Chemistry.
[22] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[23] J. Huidobro-Toro,et al. Molecular mechanism of cGMP‐mediated smooth muscle relaxation , 2000, Journal of cellular physiology.
[24] M. Houslay,et al. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. , 1998, Advances in pharmacology.
[25] T. Torphy. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.
[26] David P. Rotella,et al. INHIBITORS: CURRENT STATUS AND POTENTIAL APPLICATIONS , 2002 .
[27] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[28] M. Houslay,et al. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. , 2003, The Biochemical journal.
[29] C. Klein. Nitric oxide and the other cyclic nucleotide. , 2002, Cellular signalling.
[30] J. Fozard,et al. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. , 1996, TIPS - Trends in Pharmacological Sciences.
[31] E. Degerman,et al. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. , 1995, Archives of biochemistry and biophysics.
[32] C. Stief,et al. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: From bench to bedside , 2001, World Journal of Urology.
[33] A. Robichaud,et al. The next generation of PDE4 inhibitors. , 2001, Current opinion in chemical biology.
[34] Y. Zhao,et al. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. , 2000, Science.
[35] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[36] M. Conti,et al. 11 – An Isoform-selective Inhibitor of Cyclic AMP-Specific Phosphodiesterase (PDE4) with Anti-inflammatory Properties , 1996 .
[37] J. Corbin,et al. PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS , 2002, International journal of clinical practice.
[38] J. Beavo,et al. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. , 2000, Current opinion in cell biology.
[39] F. Antoni. Molecular Diversity of Cyclic AMP Signalling , 2000, Frontiers in Neuroendocrinology.
[40] C. Sargent,et al. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. , 2000, Immunopharmacology.
[41] Yongge Liu,et al. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. , 2006, Cardiovascular drug reviews.
[42] S. Jin,et al. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling , 2002, Trends in Endocrinology & Metabolism.